TQC3721 suspension for inhalation

DRUG5 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 1

A Clinical Trial of TQC3721 Suspension for Inhalation

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease

Start: 2021-10-18End: 2022-12-31Target: 114Updated: 2021-10-25

Phase 2

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

TerminatedNCT05292196

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease (COPD)

Start: 2022-05-20End: 2023-12-05Updated: 2025-04-20

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

CompletedNCT05987371

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease

Start: 2023-08-23End: 2024-04-23Updated: 2025-04-17

Phase 3

Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Not yet recruitingNCT07147946

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease

Start: 2025-09-30End: 2027-06-30Target: 666Updated: 2025-09-10

Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Not yet recruitingNCT07464587

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease

Start: 2026-03-01End: 2027-04-01Target: 800Updated: 2026-03-11